Nutritional status and TB treatment outcomes in Addis Ababa, Ethiopia: An ambi-directional cohort study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
09
2020
accepted:
16
02
2021
entrez:
2
3
2021
pubmed:
3
3
2021
medline:
15
10
2021
Statut:
epublish
Résumé
Remaining underweight during Tuberculosis (TB) treatment is associated with a higher risk of unsuccessful TB treatment outcomes and relapse. Previous studies conducted in Ethiopia found that bodyweight not adjusted for height at the start of treatment is associated with poor treatment outcomes. However, the association of body mass index (BMI) and weight change during treatment with treatment outcomes has not been studied. We aimed to investigate the association of BMI at the time of diagnosis and after two months of treatment and TB treatment outcomes. Using an ambi-directional cohort study design (retrospective and prospective), a total of 456 participants were enrolled among 30 randomly selected public health centers residing within six sub-cities of Addis Ababa, Ethiopia. Data were collected using medical chart abstraction and face to face interviews. We compared TB treatment outcomes in persons with a body mass index (BMI) <18.5kg/m2 (underweight) versus persons with BMI ≥18.5kg/m2 (normal or overweight) at treatment initiation and after two months of treatment. Treatment was classified as successful in persons who were free of symptoms and had a negative sputum smear for acid-fast bacilli at the end of the 6-month treatment course. We analysed outcomes using univariable and multivariable logistic regression with 95% CI and p value< 0.05. Of enrolled study participants, 184 (40.4%) were underweight and 272 (59.6%) were normal or overweight. Body mass index (BMI ≥18.5kg/m2) at the start and second month of treatment were independent predictors for successful treatment outcome (AOR = 2.15; 95% CI: 1.05, 4.39) and (AOR = 3.55; 95% CI: 1.29, 9.73), respectively. The probability of treatment success among patients with BMI≥18.5kg/m2 at the start and second month of treatment was 92.9% and 97.1%, respectively versus 86.5% and 91.7% in patients with BMI<18.5kg/m2. Bodyweight not adjusted for height and change in the bodyweight after the second and sixth months of treatment were not significantly associated with treatment success. In persons treated for TB disease, being underweight at baseline and after two months of treatment was a predictor for unsuccessful treatment outcomes. Nutritional assessment, counselling, and management are important components of TB treatment programs with the potential to improve treatment outcomes.
Sections du résumé
BACKGROUND
Remaining underweight during Tuberculosis (TB) treatment is associated with a higher risk of unsuccessful TB treatment outcomes and relapse. Previous studies conducted in Ethiopia found that bodyweight not adjusted for height at the start of treatment is associated with poor treatment outcomes. However, the association of body mass index (BMI) and weight change during treatment with treatment outcomes has not been studied. We aimed to investigate the association of BMI at the time of diagnosis and after two months of treatment and TB treatment outcomes.
METHODS
Using an ambi-directional cohort study design (retrospective and prospective), a total of 456 participants were enrolled among 30 randomly selected public health centers residing within six sub-cities of Addis Ababa, Ethiopia. Data were collected using medical chart abstraction and face to face interviews. We compared TB treatment outcomes in persons with a body mass index (BMI) <18.5kg/m2 (underweight) versus persons with BMI ≥18.5kg/m2 (normal or overweight) at treatment initiation and after two months of treatment. Treatment was classified as successful in persons who were free of symptoms and had a negative sputum smear for acid-fast bacilli at the end of the 6-month treatment course. We analysed outcomes using univariable and multivariable logistic regression with 95% CI and p value< 0.05.
RESULTS
Of enrolled study participants, 184 (40.4%) were underweight and 272 (59.6%) were normal or overweight. Body mass index (BMI ≥18.5kg/m2) at the start and second month of treatment were independent predictors for successful treatment outcome (AOR = 2.15; 95% CI: 1.05, 4.39) and (AOR = 3.55; 95% CI: 1.29, 9.73), respectively. The probability of treatment success among patients with BMI≥18.5kg/m2 at the start and second month of treatment was 92.9% and 97.1%, respectively versus 86.5% and 91.7% in patients with BMI<18.5kg/m2. Bodyweight not adjusted for height and change in the bodyweight after the second and sixth months of treatment were not significantly associated with treatment success.
CONCLUSION
In persons treated for TB disease, being underweight at baseline and after two months of treatment was a predictor for unsuccessful treatment outcomes. Nutritional assessment, counselling, and management are important components of TB treatment programs with the potential to improve treatment outcomes.
Identifiants
pubmed: 33651842
doi: 10.1371/journal.pone.0247945
pii: PONE-D-20-29191
pmc: PMC7924797
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0247945Subventions
Organisme : FIC NIH HHS
ID : D43 TW009127
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI144040
Pays : United States
Déclaration de conflit d'intérêts
The authors declare they have no conflict of interest.
Références
BMC Infect Dis. 2014 Jul 02;14:360
pubmed: 24990578
PLoS One. 2015 Dec 15;10(12):e0144244
pubmed: 26669737
BMC Res Notes. 2019 Nov 19;12(1):751
pubmed: 31744538
BMC Infect Dis. 2011 May 16;11:127
pubmed: 21575187
BMC Public Health. 2012 Jul 23;12:537
pubmed: 22824524
Int J Tuberc Lung Dis. 2013 Jun;17(6):800-6
pubmed: 23676165
Trans R Soc Trop Med Hyg. 2002 May-Jun;96(3):291-4
pubmed: 12174782
Braz J Infect Dis. 2013 Sep-Oct;17(5):521-8
pubmed: 23830051
Br J Nutr. 2012 Jan;107(2):263-71
pubmed: 21729372
PLoS One. 2013 Oct 24;8(10):e77979
pubmed: 24205052
BMC Infect Dis. 2017 Feb 8;17(1):132
pubmed: 28178936
Indian J Med Res. 2016 Jul;144(1):11-20
pubmed: 27834321
BMC Pulm Med. 2019 Oct 21;19(1):182
pubmed: 31638950
Am J Clin Nutr. 2004 Aug;80(2):460-5
pubmed: 15277171
PLoS One. 2013 May 16;8(5):e64622
pubmed: 23696901
Br J Nutr. 2011 Feb;105(3):400-8
pubmed: 20875187
BMC Public Health. 2016 Aug 25;16:883
pubmed: 27561794
Int J Tuberc Lung Dis. 2016 Jul;20(7):857-63
pubmed: 27287634
PLoS One. 2016 Feb 26;11(2):e0150560
pubmed: 26918458
Eur J Clin Nutr. 2013 Nov;67(11):1122-8
pubmed: 23942176
PLoS One. 2011 Apr 08;6(4):e18474
pubmed: 21494617
Lung India. 2009 Jan;26(1):9-16
pubmed: 20165588
Int J Tuberc Lung Dis. 2004 Feb;8(2):211-7
pubmed: 15139450
Int J Tuberc Lung Dis. 2008 Oct;12(10):1153-9
pubmed: 18812045
Int J Tuberc Lung Dis. 2013 Jan;17(1):61-6
pubmed: 23146565
Am J Respir Crit Care Med. 2006 Aug 1;174(3):236-7
pubmed: 16864715
PLoS One. 2012;7(4):e35948
pubmed: 22545150
Thorax. 1996 Feb;51(2):132-6
pubmed: 8711642
Medicine (Baltimore). 2016 Jan;95(1):e2300
pubmed: 26735532
PLoS One. 2017 Jan 13;12(1):e0170104
pubmed: 28085951